Trade Summary

4 days ago, Venker Eric, serving as President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 200,000 shares at $33.16 per share, for a total transaction value of $6,631,267.64. Following this transaction, Venker Eric now holds 1,613,063 shares of ROIV.

This sale represents a 11.03% decrease in Venker Eric's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Wednesday, June 24, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 26, 2026 at 6:13 PM ET, 2 days after the trade was made.

Roivant Sciences Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.